Subsequently, we developed a prognostic risk model based on CDKN1A, KLF2, and IFNG expression that significantly stratifies DLBCL patients into distinct risk groups, thereby potentially informing personalized treatment strategies. This evidence concerns the gene KLF2 and diffuse large B-cell lymphoma.